Evidence map›Paper›PMID 39011096›Full record

ArticleResearch square2024

A double-masked, sham-controlled trial of rose bengal photodynamic therapy for the treatment of fungal and acanthameoba keratitis: Rose Bengal Electromagnetic Activation with Green Light for Infection Reduction (REAGIR) Study.

Venkatesh Prajna, Lalitha Prajna, Sankalp Sharma, Denise de Freitas, Ana Luisa Höfling-Lima, Nicole Varnado, Sarah Abdelrahman, Victoria Cavallino, Ben Arnold, Tom Lietman and 1 more

Registry-linked trialAbstract readPreprint
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05110001 (Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05110001 phase3completednot on this map

Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction

TypeinterventionalSponsorUniversity of California, San FranciscoRan2022 to 2025Enrolled330ConditionsAcanthamoeba Keratitis, Fungal KeratitisArmsMoxifloxacin Ophthalmic, Chlorhexidine Gluconate, Natamycin, Rose Bengal, Placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Venkatesh PrajnaAravind Eye Care System.
Lalitha PrajnaAravind Eye Hospital.
Sankalp SharmaAravind Eye Hospital.
Denise de FreitasFederal University of Sao Paulo: Universidade Federal de Sao Paulo.
Ana Luisa Höfling-LimaFederal University of Sao Paulo: Universidade Federal de Sao Paulo.
Nicole VarnadoStanford University School of Medicine.
Sarah AbdelrahmanFI Proctor Foundation.
Victoria CavallinoFI Proctor Foundation.
Ben ArnoldFI Proctor Foundation.
Tom LietmanFI Proctor Foundation.
Jennifer Rose-NussbaumerStanford University School of Medicine.

Funding

Steroids and Cross-linking for Ulcer Treatment (SCUT II)UG1EY028518 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIETMAN, THOMAS M, ROSE-NUSSBAUMER, JENNIFER · 2019 to 2023
$3.9M
Predictions of Response to Treatment in Fungal KeratitisK23EY025025 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSE-NUSSBAUMER, JENNIFER · 2015 to 2019
$1.2M
NEI NIH HHS K23 EY025025NEI NIH HHS UG1 EY028518
6 · The paper itself

Abstract

Background: Infectious keratitis secondary to fungus or acanthamoeba often has a poor outcome despite receiving the best available medical therapy. Methods: This international, randomized, sham and placebo controlled 2-arm clinical trial, randomizes patients with smear positive fungal and acanthameoba and smear negative corneal ulcers in a 1:1 fashion to one of two treatment arms: 1) Topical antimicrobial plus sham RB-PDT or 2) Topical antimicrobial plus RB-PDT. Discussion: We anticipate that RB-PDT will improve best spectacle corrected visual acuity and also reduce complications such as corneal perforation and the need for therapeutic penetrating keratoplasty. This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH-Funded Clinical Trial Information and the Clinical Trials Registration and Results Information Submission rule. Our results will be disseminated via clinicaltrials.gov website, meetings, and journal publications. Our data will also be available upon reasonable request. Trial Registration: NCT, NCT05110001, Registered November 5, 2021. https://www.clinicaltrials.gov/study/NCT05110001.

Indexed as

corneaInfectious keratitisRB-PDT

Identifiers

PMID39011096
PMCPMC11247944

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.